Clinical Effectiveness and safety of Peramivir in the Treatment of Severe Influenza A with Pneumonia

Evaluation of clinical efficacy and prognostic risk factors of peramivir antiviral therapy for severe influenza A complicated with primary pneumonia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021135

Enrollment

Unknown

Registered

2019-01-29

Start date

2019-01-28

Completion date

Unknown

Last updated

2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Influenza A with Pneumonia

Interventions

Group A:Oral oseltamivir

Group B:Intravenous drip of peramivir

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The pharyngeal swabs of the patients were tested with nucleic acid test kits for influenza A and B pathogens, and the results showed that the patients were positive for influenza A; 2. Patients aged 18 years or older, and male or female are not limited. 3. combined with pneumonia;

Exclusion criteria

Exclusion criteria: (1) vaccinated for influenza within the past six months; (2) taking M2 channel blockers (e.g., amantadine, rimantadine) and neuraminidase inhibitors (oseltamivir, zanamivir, etc.) within the past one month.

Design outcomes

Primary

Measure	Time frame
The duration of virus nucleic acid positivity;Biochemical indexes;	—

Secondary

Measure	Time frame
Time to fever alleviation;The remission time of clinical symptoms;	—

Countries

China

Contacts

Public ContactJinna Wang

Suqian People's Hospital of Nanjing Gulou Hospital Group

593372527@qq.com+86 15751514806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026